[HTML][HTML] Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy

Q Zhang, R Xiang, S Huo, Y Zhou, S Jiang… - Signal transduction and …, 2021 - nature.com
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …

Advances in nanomaterial-based platforms to combat COVID-19: Diagnostics, preventions, therapeutics, and vaccine developments

N Mahmud, MI Anik, MK Hossain, MI Khan… - ACS Applied Bio …, 2022 - ACS Publications
The COVID-19 pandemic caused by the SARS-CoV-2, a ribonucleic acid (RNA) virus that
emerged less than two years ago but has caused nearly 6.1 million deaths to date. Recently …

CoV-AbDab: the coronavirus antibody database

MIJ Raybould, A Kovaltsuk, C Marks… - Bioinformatics, 2021 - academic.oup.com
Motivation The emergence of a novel strain of betacoronavirus, SARS-CoV-2, has led to a
pandemic that has been associated with over 700 000 deaths as of August 5, 2020 …

[HTML][HTML] Real-time environmental surveillance of SARS-CoV-2 aerosols

JV Puthussery, DP Ghumra, KR McBrearty… - Nature …, 2023 - nature.com
Real-time surveillance of airborne SARS-CoV-2 virus is a technological gap that has eluded
the scientific community since the beginning of the COVID-19 pandemic. Offline air sampling …

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

P Pymm, A Adair, LJ Chan… - Proceedings of the …, 2021 - National Acad Sciences
Neutralizing antibodies are important for immunity against SARS-CoV-2 and as therapeutics
for the prevention and treatment of COVID-19. Here, we identified high-affinity nanobodies …

Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies

T Güttler, M Aksu, A Dickmanns, KM Stegmann… - The EMBO …, 2021 - embopress.org
Abstract Monoclonal anti‐SARS‐CoV‐2 immunoglobulins represent a treatment option for
COVID‐19. However, their production in mammalian cells is not scalable to meet the global …

An update of anti-viral treatment of COVID-19.

S ŞİMŞEK YAVUZ… - Turkish journal of …, 2021 - search.ebscohost.com
Background/aim: Currently there is not an effective antiviral treatment for COVID-19, but a
large number of drugs have been evaluated since the beginning of the pandemic, and many …

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape

FD Mast, PC Fridy, NE Ketaren, J Wang, EY Jacobs… - Elife, 2021 - elifesciences.org
The emergence of SARS-CoV-2 variants threatens current vaccines and therapeutic
antibodies and urgently demands powerful new therapeutics that can resist viral escape. We …

[HTML][HTML] Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment

NA Valdez-Cruz, E García-Hernández, C Espitia… - Microbial cell …, 2021 - Springer
SARS-CoV-2 is a novel β-coronavirus that caused the COVID-19 pandemic disease, which
spread rapidly, infecting more than 134 million people, and killing almost 2.9 million thus far …

[HTML][HTML] Research progress and applications of nanobody in human infectious diseases

Y Mei, Y Chen, JP Sivaccumar, Z An, N Xia… - Frontiers in …, 2022 - frontiersin.org
Infectious diseases, caused by pathogenic microorganisms, are capable of affecting crises.
In addition to persistent infectious diseases such as malaria and dengue fever, the vicious …